Zobrazeno 1 - 6
of 6
pro vyhledávání: '"L, Serrano De Lucas"'
Autor:
B San Jose Ruiz, Á. Sebastián Leza, M. de Miguel Cascon, J.L. Fonseca Legrand, B Baza Martinez, L. Serrano de Lucas, A Bustinza Txertudi, S. Sautua Larreategi, M.T. Chirivella Ramón, L.R. López-Giménez
Publikováno v:
Revista de Calidad Asistencial. 31:36-44
Resumen Objetivo Identificar y cuantificar las discrepancias entre el tratamiento prescrito al ingreso hospitalario y el tratamiento cronico del paciente. Identificar variables que puedan utilizarse en la seleccion de los pacientes mas susceptibles d
Autor:
B, San José Ruiz, L, Serrano De Lucas, L R, López-Giménez, B, Baza Martínez, S, Sautua Larreategi, A, Bustinza Txertudi, Á, Sebastián Leza, M T, Chirivella Ramón, J L, Fonseca Legrand, M, de Miguel Cascon
Publikováno v:
Revista de calidad asistencial : organo de la Sociedad Espanola de Calidad Asistencial. 31
To quantify and to classify the discrepancies between the admission treatment and the usual patient treatment. To determine the variables that predict those patients that will have more benefit from medication reconciliation.A prospective medication
Autor:
A Bustinza Txertudi, A De Basagoiti Gorordo, Z Baskaran Kaltzakorta, A Belaustegi Foronda, B San Jose Ruiz, B Baza Martinez, L. Serrano de Lucas, I Bilbao Meseguer, J Hernandez Goicoechea, MA Gil Lemus
Publikováno v:
European Journal of Hospital Pharmacy. 20:A40.2-A40
Background Glucarpidase (Voraxaze) is effective in the treatment of methotrexate (MTX)-induced renal dysfunction but many cases this can be handled with standard treatment. Purpose To describe the progress of a patient with MTX-induced renal failure
Autor:
B. Baza, A. de Basagoiti, L. Serrano de Lucas, E. Rodriguez, A Belaustegi, J Hernández, I. Bilbao, S Sautua, M. Castaño, Z. Baskaran
Publikováno v:
European Journal of Hospital Pharmacy. 20:A40.1-A40
Background Linezolid is an antimicrobial approved for the treatment of hospital or community-acquired pneumonia and complicated skin and soft tissue infections due to Gram positive bacteria. Its use, though effective, is not free from possible harm.
Autor:
A. Bustinza, I. Bilbao, Z. Baskaran, B. San José, M. Castaño, L. Serrano de Lucas, J Hernández
Publikováno v:
European Journal of Hospital Pharmacy. 19:235.3-236
Background During recent years, an increase in the incidence of Invasive Fungal Infections (IFI) has been observed, in parallel to a progressive shift of invasive species from Candida albicans to fungi resistant to previously-effective treatments. Th
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.